NMN Dosage for Longevity: What the Clinical Trial Data Actually Supports

The published clinical trials on NMN — Yoshino et al. 2021, Liao et al. 2021, Yi et al. 2023, Igarashi et al. 2022 — use daily doses between 250 mg and 1,000 mg, with the bulk of the positive endpoint data sitting at 500 mg or above. Most over-the-counter NMN supplements deliver 125–300 mg per serving. The dose gap between what the trials use and what the shelf delivers is the single most important question a buyer of any NMN product needs to answer before paying for the bottle.

NMN — β-nicotinamide mononucleotide — is the precursor that reliably raises serum NAD+ in human trials. NAD+ falls roughly 50 percent between age 20 and 50, with another 20 percent drop by 65. The fall is one of the most replicable biological correlates of aging in the published literature. The intervention — restoring NAD+ via precursor supplementation — has now been studied across six published RCTs covering metabolic, vascular, walking-speed, and biomarker endpoints. The dose-response curves from those trials are what should drive a buying decision. Not the marketing copy on the bottle.

What follows: the trial-by-trial dose breakdown, the body-weight scaling logic, the timing protocol that matters, the form differences that matter, and the practical buying filter for translating the trial data into a real-world supplement decision.

The Trial-by-Trial NMN Dose Breakdown

Yoshino et al. 2021 — 250 mg, prediabetic postmenopausal women, 10 weeks. Published in Science. Twenty-five prediabetic, overweight, postmenopausal women received 250 mg NMN daily versus placebo for 10 weeks. Result: a 25 percent improvement in skeletal muscle insulin sensitivity (the primary endpoint) and significant upregulation of muscle gene expression related to insulin signaling. The 250 mg dose was effective for this metabolic endpoint in this specific population. The trial is the floor of the supportive evidence — the lowest dose that produced a measurable endpoint change.

Liao et al. 2021 — 300 mg, recreationally trained men, 6 weeks. Published in the Journal of the International Society of Sports Nutrition. Forty-eight amateur male runners received 300, 600, or 1,200 mg NMN daily versus placebo for 6 weeks. Result: dose-dependent improvement in aerobic capacity (VO2 max delta) with the highest gain at 600 mg. The 1,200 mg arm showed no additional benefit beyond 600 mg, suggesting a plateau in the dose-response curve. The trial is the cleanest dose-finding data published to date: 300 mg meaningful, 600 mg better, 1,200 mg no additional benefit.

Yi et al. 2023 — 300 mg, 600 mg, 900 mg, middle-aged and older adults, 60 days. Published in GeroScience. Eighty adults aged 40–65 received 300, 600, or 900 mg NMN daily versus placebo for 60 days. Result: dose-dependent serum NAD+ elevation across all three arms, with the 600 mg and 900 mg arms showing significant improvements in walking distance, blood biological age (using a composite biomarker index), and HOMA-IR insulin resistance. The 300 mg arm raised NAD+ but did not move the downstream endpoints reliably. The trial is the strongest evidence that 600 mg is the practical threshold for clinically-meaningful effects in the general aging population.

Igarashi et al. 2022 — 250 mg, older men, 12 weeks. Published in npj Aging. Forty-two older Japanese men received 250 mg NMN daily versus placebo for 12 weeks. Result: significant improvements in grip strength and gait speed, two of the most-validated frailty endpoints in geriatric medicine. The 250 mg dose was effective in this population — but the trial duration was longer (12 weeks vs. 6 weeks in Liao) and the population was older. Older populations may show benefit at lower doses given the steeper baseline NAD+ deficit.

Martens et al. 2018 — 1,000 mg, older adults, 6 weeks (nicotinamide riboside, related precursor). Published in Nature Communications. Thirty older adults received 1,000 mg NR daily versus placebo for 6 weeks. Result: 60 percent increase in serum NAD+ and a measurable reduction in systolic blood pressure and aortic stiffness in the subgroup with stage 1 hypertension. The trial is included here because NR converts to NMN before reaching the cellular NAD+ pool — the dose-response data informs both precursors.

The pattern across all five trials is consistent: 250–300 mg is the minimum effective dose for specific endpoints in specific populations. 500–600 mg is the dose where most generalist longevity endpoints (walking speed, NAD+ restoration, biomarker improvements) reliably move. 1,000 mg is the upper bound of the published clinical literature; doses above this have no supportive trial data and increasing cost.

Body-Weight Scaling: Why 500 mg Is Not the Same Dose for Everyone

The trial doses above are reported as absolute milligrams per day, not milligrams per kilogram of body weight. This matters. A 500 mg dose in a 60 kg postmenopausal woman is 8.3 mg/kg. The same 500 mg dose in a 100 kg adult male is 5 mg/kg — 40 percent less per unit of body mass.

The animal NAD+ precursor literature uses mg/kg dosing almost universally, and the dose-response curves there are unambiguous: more body mass requires proportionally more precursor to reach the same intracellular NAD+ ceiling. The translation to human dosing is approximate, but the implication is operational: a 100 kg adult buying a "500 mg per day" NMN product is delivering a meaningfully lower per-kg dose than the 60 kg subject in the Yoshino trial. Whether that lower dose is enough depends on the endpoint being targeted.

The pragmatic dosing heuristic the longevity-focused clinicians have converged on: 5–10 mg per kg of bodyweight daily for general longevity-protocol use. That puts a 70 kg adult in the 350–700 mg range, a 90 kg adult in the 450–900 mg range, and a 50 kg adult in the 250–500 mg range. Bryan Johnson, at his published 90 kg bodyweight, takes 900 mg NMN daily — squarely inside this heuristic.

Timing: Morning vs. Evening, Fed vs. Fasted

NMN's circadian and pharmacokinetic profile matters more than most supplement marketing acknowledges. Endogenous NAD+ follows a circadian rhythm — peaking in the morning, declining through the day, and falling to its trough overnight. Exogenous NMN supplementation in the morning aligns with the body's natural NAD+ utilization peak, supporting the energy-demanding activities of the active phase. Evening dosing risks interfering with the natural overnight NAD+ trough that drives mitochondrial autophagy and the sirtuin-mediated repair processes during sleep.

The published trials uniformly use morning dosing. Yoshino specifies "in the morning before breakfast." Liao specifies "before training in the morning." Yi specifies "with breakfast." None of the supportive endpoint trials use evening dosing. The longevity-focused clinicians have converged on the same recommendation: NMN in the morning, on an empty stomach or with a small low-fat meal, not in the evening.

The fed-versus-fasted question is less settled. NMN's oral bioavailability is reasonable in both contexts, but a fasted-state pulse produces a sharper peak in plasma NAD+. For the longevity-targeted user, morning fasted dosing is the default recommendation. For users who experience GI sensitivity to fasted supplementation, taking NMN with a low-fat breakfast remains supportive of the trial protocols.

Form Matters: β-NMN vs. α-NMN, Sublingual vs. Capsule, Stability

Three form-related variables that buyer attention rarely focuses on but that meaningfully change the effective dose delivered:

β-NMN versus α-NMN. NMN has two isomers. The β-isomer is the biologically active form used in every published clinical trial. The α-isomer is a cheaper byproduct of some manufacturing processes that does not contribute to NAD+ restoration. Reputable suppliers specify β-NMN content explicitly. Bottles that list only "NMN" without isomer specification may contain meaningful α-NMN fractions that reduce effective dose. The premium specification is "≥99% β-NMN by HPLC" — the same purity standard the trial-grade material met.

Sublingual versus capsule. Sublingual NMN delivery (lozenges, powder under the tongue) bypasses first-pass hepatic metabolism and theoretically delivers more intact NMN to the bloodstream. The published trial data overwhelmingly uses oral capsule delivery — not sublingual — and the endpoint data is robust. Sublingual delivery is a reasonable add-on, particularly for users targeting the highest dose ranges, but the evidence base does not require it. A high-purity oral capsule at the trial-validated dose is the supported baseline.

Stability and storage. NMN degrades in the presence of heat, moisture, and light. Bottles stored in a warm bathroom drawer for six months may deliver meaningfully less than the labeled dose. The published manufacturing standard is cool, dry, dark storage — and the practical recommendation is refrigeration after opening for users running the higher dose ranges. A bottle that has been in a warm car for an afternoon is not the same bottle that left the manufacturer.

What This Means for the Buying Decision

The trial data, the body-weight scaling, the timing protocol, and the form variables collapse into a small set of buying filters that translate the published literature into a supplement decision:

• Per-serving dose. 500 mg minimum for the general longevity user. 600–900 mg if the user is above 80 kg or targeting the stronger endpoint data from the Yi 2023 and Liao 2021 trials.
• Isomer specification. β-NMN explicitly stated. ≥99% β-NMN by HPLC is the premium tier.
• Form. Oral capsule is the supported default. Sublingual is optional, not required.
• Co-formulation with resveratrol. Mechanism-supported. Resveratrol activates SIRT1, the enzyme whose substrate is the NAD+ NMN restores. The dose-multiplicative effect is well-characterized in the cellular and animal literature.
• QC documentation. Third-party HPLC purity, heavy metals below USP <232> limits, microbiology below USP <2021>/<2022> limits. Each batch should ship with a Certificate of Analysis on request.
• Timing. Morning dose, fasted or with a small low-fat meal. Not in the evening.
• Storage. Cool, dry, dark. Refrigerated after opening if running 600 mg or above.

The NMN + Resveratrol Complex 500mg hits these specifications. β-NMN at the 500 mg trial-validated dose. Trans-resveratrol at 250 mg — the dose used in the Sinclair lab's published cardiovascular and sirtuin-activation work. Co-formulation is mechanism-informed, not marketing-informed. The per-batch QC includes HPLC identity and purity verification, heavy metals testing, and microbiology screening. The bottle ships with the protocol-aligned timing instructions.

For users above 80 kg targeting the stronger Yi 2023 endpoint data, two capsules daily delivers 1,000 mg NMN + 500 mg resveratrol — squarely inside the upper-range trial protocol Bryan Johnson's published regimen uses.

What the Trial Data Does Not Yet Settle

Three open questions in the NMN literature that the available trials have not yet answered with high confidence:

Long-term safety beyond 12 months. The longest published NMN trials are in the 12-week range. The safety data is encouraging — no serious adverse events in the trial populations, no signal of off-target effects in monitored biomarkers — but the multi-year exposure data does not yet exist. The pragmatic position: the safety profile of the trials is reassuring, the biological logic is well-established, and the comparison should be with the safety profile of doing nothing while NAD+ falls by 0.5–1 percent per year.

Optimal long-term dose schedule. Continuous daily dosing is what every trial has used. Whether intermittent dosing (5 days on, 2 days off) or cyclical dosing produces superior or comparable benefit is unknown. The animal literature suggests continuous low-dose may produce different effects than periodic high-dose, but the human data does not yet exist.

Co-supplementation interactions. NMN, resveratrol, and TMG (trimethylglycine) are commonly co-supplemented in the longevity protocols of Sinclair, Attia, and the Bryan Johnson Blueprint. TMG is included specifically to manage potential methyl group depletion from NMN-driven NAD+ recycling. The interaction data is plausible mechanistically but the human RCT data on the three-supplement stack does not yet exist. The pragmatic position: the resveratrol-NMN combination is well-supported; TMG addition is a defensible second-tier add for users running the 900-1,000 mg NMN dose ranges.

The trial literature on NMN is one of the cleanest in the entire longevity supplement category. The doses that work are documented. The endpoints that respond are documented. The timing protocol is documented. What remains is the buyer's job — translate the published doses into the per-serving dose, the per-day dose, the body-weight-scaled dose, and the per-bottle QC standard that match the trial protocol the user is trying to replicate.

This article is part of the PureLongevity research library. The full deep-dive on NAD+ restoration, the NMN-resveratrol stack mechanism, and the 60-day biomarker checkpoint protocol is available in The Cellular Powerhouse Protocol. PureLongevityToday may earn a commission from purchases made through links in this article. Nothing here constitutes medical advice. Consult a qualified clinician before changing a supplement protocol.